Karyopharm (KPTI) director Christy Oliger receives 15,508 RSU equity award

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. director Christy J. Oliger received an equity award in the form of 15,508 shares of Common Stock, reported as a grant of restricted stock units (RSUs) with a price of $0.00 per share as compensation rather than a market purchase.

The award was made under the company’s 2022 Equity Incentive Plan. Each RSU converts into one share of common stock, vesting 100% on May 21, 2027. However, actual share delivery is deferred until the earlier of the director’s separation from service or a qualifying change-in-control event, so the economic benefit is realized over time.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Oliger Christy J.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,508	$0.00	--

Holdings After Transaction: Common Stock — 15,508 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 15,508 shares Grant price: $0.00 per share Post-transaction holdings: 15,508 shares +1 more

4 metrics

RSU grant size 15,508 shares Restricted stock unit award to director on May 21, 2026

Grant price $0.00 per share Stated price for RSU grant, compensation-related

Post-transaction holdings 15,508 shares Total common stock reported following the transaction

Vesting date May 21, 2027 RSUs vest 100% on this date

Key Terms

restricted stock units ("RSUs"), 2022 Equity Incentive Plan, change-in-control event

3 terms

restricted stock units ("RSUs") financial

"Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2022 Equity Incentive Plan financial

"pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended"

change-in-control event financial

"delivery of the shares is deferred until the earlier of ... and (b) a change-in-control event"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oliger Christy J.

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		15,508(1)	A	$0	15,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.

	/s/ Nancy Smith, Attorney-in-Fact for Christy Oliger	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Karyopharm Therapeutics (KPTI) director Christy J. Oliger report on this Form 4?

Christy J. Oliger reported receiving an equity grant of 15,508 restricted stock units of Karyopharm Therapeutics common stock. This was a compensation-related award, not an open-market purchase, and was issued at a stated price of $0.00 per share under the company’s equity plan.

How many Karyopharm Therapeutics (KPTI) shares did Christy J. Oliger hold after the reported transaction?

After the transaction, Christy J. Oliger was reported as holding 15,508 shares of Karyopharm Therapeutics common stock. This balance reflects the newly granted restricted stock units, which convert to common shares on a one-for-one basis upon vesting and subsequent share delivery conditions being met.

What are the vesting terms of Christy J. Oliger’s RSU grant at Karyopharm Therapeutics (KPTI)?

The restricted stock units vest 100% on May 21, 2027, according to the disclosure. Although vesting occurs then, delivery of the underlying Karyopharm Therapeutics common shares is deferred until the earlier of the director’s separation from service or a qualifying change-in-control event.

Was Christy J. Oliger’s Karyopharm Therapeutics (KPTI) Form 4 transaction a market buy or sell?

The Form 4 shows a grant acquisition, not a market buy or sell. The 15,508 shares were received as a restricted stock unit award priced at $0.00 per share, so this reflects compensation rather than an open-market trading decision involving cash consideration.

Under which plan were the Karyopharm Therapeutics (KPTI) RSUs granted to Christy J. Oliger?

The restricted stock units were granted pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. This plan governs equity compensation awards, and in this case provides RSUs that convert into common stock on a one-for-one basis upon vesting and share delivery.